Ildong Pharmaceutical Co., Ltd. (KRX:249420)
South Korea · Delayed Price · Currency is KRW 27,400
+800 (3.01%)
Apr 8, 2026, 3:30 PM KST
Ildong Pharmaceutical Cash Flow Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Net Income | 27,664 | -4,576 | -78,928 | -141,585 | -99,705 |
Depreciation & Amortization | 22,576 | 25,935 | 28,319 | 29,545 | 29,311 |
Loss (Gain) From Sale of Assets | 2,146 | 4,908 | -1,133 | 282.22 | 101.53 |
Asset Writedown & Restructuring Costs | 2,536 | 9,857 | 3,492 | 19,004 | 550.27 |
Loss (Gain) From Sale of Investments | -7,643 | -1,955 | -439.72 | -2,325 | 862.82 |
Loss (Gain) on Equity Investments | -283.69 | 273.49 | 0.36 | 0.54 | 1.67 |
Stock-Based Compensation | 215.08 | 129.79 | -5.73 | 18.09 | 16.55 |
Provision & Write-off of Bad Debts | 243.8 | 303.04 | -574.49 | -85.1 | -1,142 |
Other Operating Activities | -1,037 | 1,449 | 24,140 | 56,020 | 60,178 |
Change in Accounts Receivable | -2,654 | 3,634 | -2,089 | -1,407 | -1,857 |
Change in Inventory | -13,506 | -2,508 | 13,852 | -15,532 | 6,617 |
Change in Accounts Payable | 229.27 | -2,973 | 4,235 | 7,936 | 2,339 |
Change in Other Net Operating Assets | -11,537 | -6,185 | -27,484 | -5,412 | -8,639 |
Operating Cash Flow | 18,951 | 28,293 | -36,615 | -53,541 | -11,366 |
Operating Cash Flow Growth | -33.02% | - | - | - | - |
Capital Expenditures | -13,647 | -10,679 | -13,201 | -11,873 | -14,626 |
Sale of Property, Plant & Equipment | 161.71 | 29,336 | 307.01 | 67.5 | 38.14 |
Divestitures | 184.32 | 79.74 | - | - | 4,142 |
Sale (Purchase) of Intangibles | -3,637 | -1,150 | -1,968 | -6,401 | -4,876 |
Investment in Securities | 6,649 | 12,759 | -1,601 | -7,401 | -26,180 |
Other Investing Activities | -913.62 | -344.22 | 1,025 | -842.62 | 1,133 |
Investing Cash Flow | -2,279 | 18,458 | -20,360 | -26,435 | -43,368 |
Short-Term Debt Issued | 14,715 | 15,030 | 84,500 | 23,000 | 141,600 |
Long-Term Debt Issued | - | 50,000 | 29,250 | 17,000 | 99,400 |
Total Debt Issued | 14,715 | 65,030 | 113,750 | 40,000 | 241,000 |
Short-Term Debt Repaid | -21,920 | -87,519 | -48,700 | -20,000 | -133,600 |
Long-Term Debt Repaid | -26,369 | -3,573 | -4,850 | -23,118 | -10,723 |
Total Debt Repaid | -48,289 | -91,092 | -53,550 | -43,118 | -144,323 |
Net Debt Issued (Repaid) | -33,575 | -26,062 | 60,200 | -3,118 | 96,677 |
Issuance of Common Stock | - | - | 124.83 | - | 1,745 |
Repurchase of Common Stock | -0.87 | -0.17 | -1,942 | - | - |
Dividends Paid | -60.16 | -76.8 | -160 | -120 | - |
Other Financing Activities | 9,547 | -366.08 | -70.4 | -49.31 | -0 |
Financing Cash Flow | -24,088 | -27,854 | 58,152 | -3,287 | 104,316 |
Foreign Exchange Rate Adjustments | -4.84 | 112.18 | -64.19 | -177.2 | 440.44 |
Net Cash Flow | -7,422 | 19,009 | 1,112 | -83,440 | 50,022 |
Free Cash Flow | 5,304 | 17,614 | -49,817 | -65,413 | -25,992 |
Free Cash Flow Growth | -69.89% | - | - | - | - |
Free Cash Flow Margin | 0.94% | 2.86% | -8.29% | -10.26% | -4.64% |
Free Cash Flow Per Share | 172.61 | 630.60 | -1843.01 | -2483.08 | -1092.76 |
Cash Interest Paid | 7,995 | 13,534 | 10,412 | 5,643 | 4,041 |
Cash Income Tax Paid | 1,902 | 560.83 | 724.88 | 2,524 | -290.57 |
Levered Free Cash Flow | -20,183 | -6,707 | 5,487 | -159,418 | 101,154 |
Unlevered Free Cash Flow | -12,574 | 3,254 | 14,690 | -153,300 | 107,752 |
Change in Working Capital | -27,467 | -8,032 | -11,485 | -14,416 | -1,540 |
Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.